Literature DB >> 32386943

Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis.

Xiaohui Duan1, Hui Zhang1, Lixue Zhou1, Bo Jiang1, Xianhai Mao2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32386943     DOI： 10.1016/j.dld.2020.04.005

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN： 1590-8658            Impact factor:   4.088


× No keyword cloud information.
  5 in total

Review 1.  Sintilimab: A Promising Anti-Tumor PD-1 Antibody.

Authors:  Lin Zhang; Wuqian Mai; Wenyang Jiang; Qing Geng
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

2.  Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study.

Authors:  Caiyun Nie; Huifang Lv; Yingjun Liu; Beibei Chen; Weifeng Xu; Jianzheng Wang; Xiaobing Chen
Journal:  Front Oncol       Date:  2021-09-22       Impact factor: 6.244

3.  Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors.

Authors:  Nana Huang; Chenchen Zhao; Xueyang Hu; Congjun Zhang; Fuxing Xiong; Wei Huang; Liangshan Da; Yuanyuan Shen; Hongyang Wu
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

4.  Metabolic Regulation of Hepatitis B Virus Infection in HBV-Transgenic Mice.

Authors:  Wenning Lan; Yang Wang; Zixiong Zhou; Xia Sun; Yun Zhang; Fangrong Zhang
Journal:  Metabolites       Date:  2022-03-25

Review 5.  Biosimilar monoclonal antibodies in China: A patent review.

Authors:  Jia-Wei Liu; Yu-Huan Yang; Nan Wu; Ji-Fu Wei
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.